HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $107
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on BioNTech (NASDAQ:BNTX) but has reduced the price target from $133 to $107.
January 23, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. analyst maintains a Buy rating on BioNTech but lowers the price target from $133 to $107, indicating a potential decrease in stock valuation.
The reduction in price target by HC Wainwright & Co. suggests that they see less upside potential for BioNTech's stock, which could lead to a negative short-term reaction in the market as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100